Advancements in the Treatment of Homozygous Familial Hypercholesterolemia

被引:15
作者
Bajaj, Archna [1 ]
Cuchel, Marina [1 ]
机构
[1] Univ Penn, Div Translat Med & Human Genet, Philadelphia, PA 19104 USA
关键词
Familial hypercholesterolemia; PCSK9; ANGPTL3; Apheresis; Gene therapy; TRIGLYCERIDE TRANSFER PROTEIN; DENSITY-LIPOPROTEIN RECEPTOR; GENE-THERAPY; CARDIOVASCULAR-DISEASE; LIVER-TRANSPLANTATION; BEMPEDOIC ACID; DOUBLE-BLIND; EFFICACY; CHOLESTEROL; ANGPTL3;
D O I
10.5551/jat.RV17065
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder with extreme elevations of low-density lipoprotein cholesterol (LDL-C) leading to premature atherosclerotic cardiovascular disease (ASCVD) as early as in childhood. Management of HoFH centers around aggressive and adequate reduction of LDL-C levels to slow the trajectory of ASCVD development. Historically, lowering LDL-C levels in HoFH has been challenging because of both the markedly elevated LDL-C levels (often > 400 mg/dL) and reduced response to treatment options, such as statins, for which the mechanism of action requires a functional LDL receptor. However, the treatment landscape for HoFH has rapidly progressed over the last decade. While statins and ezetimibe remain first-line treatment, patients often require addition of multiple therapies to achieve goal LDL-C levels. The PCSK9 inhibitors are an important recent addition to the available treatment options, along with lomitapide, bile acid sequestrants, and, possibly, bempedoic acid. Additionally, ANGPTL3 has emerged as an important therapeutic target, with evinacumab being the first available ANGPTL3 inhibitor on the market for the treatment of patients with HoFH. For patients who cannot achieve adequate LDL-C reduction, lipoprotein apheresis may be necessary, with the added benefit of reducing lipoprotein(a) levels that carries an added risk if also elevated in patients with HoFH. Finally, gene therapy and genome editing using CRISPR/Cas-9 are moving through clinical development and may dramatically alter the future landscape of treatment for HoFH.
引用
收藏
页码:1125 / 1135
页数:11
相关论文
共 85 条
[1]   Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance [J].
Adam, Rene C. ;
Mintah, Ivory J. ;
Alexa-Braun, Corey A. ;
Shihanian, Lisa M. ;
Lee, Joseph S. ;
Banerjee, Poulabi ;
Hamon, Sara C. ;
Kim, Hye In ;
Cohen, Jonathan C. ;
Hobbs, Helen H. ;
Van Hout, Cristopher ;
Gromada, Jesper ;
Murphy, Andrew J. ;
Yancopoulos, George D. ;
Sleeman, Mark W. ;
Gusarova, Viktoria .
JOURNAL OF LIPID RESEARCH, 2020, 61 (09) :1271-1286
[2]   The CRISPR tool kit for genome editing and beyond [J].
Adli, Mazhar .
NATURE COMMUNICATIONS, 2018, 9
[3]   A Meta-Analysis Assessing Additional LDL-C Reduction from Addition of a Bile Acid Sequestrant to Statin Therapy [J].
Alder, Madeleine ;
Bavishi, Aakash ;
Zumpf, Katelyn ;
Peterson, Jonna ;
Stone, Neil J. .
AMERICAN JOURNAL OF MEDICINE, 2020, 133 (11) :1322-1327
[4]   Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia [J].
Banach, Maciej ;
Duell, P. Barton ;
Gotto, Antonio M., Jr. ;
Laufs, Ulrich ;
Leiter, Lawrence A. ;
Mancini, G. B. John ;
Ray, Kausik K. ;
Flaim, JoAnn ;
Ye, Zhan ;
Catapano, Alberico L. .
JAMA CARDIOLOGY, 2020, 5 (10) :1124-1135
[5]   Worldwide Prevalence of Familial Hypercholesterolemia Meta-Analyses of 11 Million Subjects [J].
Beheshti, Sabina O. ;
Madsen, Christian M. ;
Varbo, Anette ;
Nordestgaard, Birge G. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (20) :2553-2566
[6]   Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia [J].
Ben-Omran, Tawfeg ;
Masana, Luis ;
Kolovou, Genovefa ;
Ariceta, Gema ;
Novoa, F. Javier ;
Lund, Allan M. ;
Bogsrud, Martin P. ;
Araujo, Maria ;
Hussein, Osamah ;
Ibarretxe, Daiana ;
Sanchez-Hernandez, Rosa M. ;
Santos, Raul D. .
ADVANCES IN THERAPY, 2019, 36 (07) :1786-1811
[7]   Lomitapide for the treatment of hypercholesterolemia [J].
Berberich, Amanda J. ;
Hegele, Robert A. .
EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (12) :1261-1268
[8]   Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia The ODYSSEY HoFH Trial [J].
Blom, Dirk J. ;
Harada-Shiba, Mariko ;
Rubba, Paolo ;
Gaudet, Daniel ;
Kastelein, John J. P. ;
Charng, Min-Ji ;
Pordy, Robert ;
Donahue, Stephen ;
Ali, Shazia ;
Dong, Yuping ;
Khilla, Nagwa ;
Banerjee, Poulabi ;
Baccara-Dinet, Marie ;
Rosenson, Robert S. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (02) :131-142
[9]   Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia [J].
Blom, Dirk J. ;
Averna, Maurizio R. ;
Meagher, Emma A. ;
Theron, Hendrik du Toit ;
Sirtori, Cesare R. ;
Hegele, Robert A. ;
Shah, Prediman K. ;
Gaudet, Daniel ;
Stefanutti, Claudia ;
Vigna, Giovanni B. ;
Larrey, Dominique ;
Bloedon, LeAnne T. ;
Foulds, Pamela ;
Rader, Daniel J. ;
Cuchel, Marina .
CIRCULATION, 2017, 136 (03) :332-335
[10]   Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France [J].
Bruckert, Eric ;
Kalmykova, Olga ;
Bittar, Randa ;
Carreau, Valerie ;
Beliard, Sophie ;
Saheb, Samir ;
Rosenbaum, David ;
Bonnefont-Rousselot, Dominique ;
Thomas, Daniel ;
Emery, Corinne ;
Khoshnood, Babak ;
Carrie, Alain .
ATHEROSCLEROSIS, 2017, 257 :130-137